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Systemic therapy of advanced stage hepatocellular carcinoma (HCC) was  
limited to the sorafenib in the past decade since 2007. Novel agents including multi-
ple targeting agents, immune checkpoint inhibitors and anti-angiogenesis reported 
efficacy in treatment. This is the first time, the combination of atezolizumab and 
bevacizumab as first-line treatment is superior to sorafenib. Standard guideline 
in advanced HCC was changing. New novel drugs increase in available including 
multiple targeting agents and immune checkpoint blockade such as Lenvatinib, 
regorafenib, cabozantinib, ramucirumab and immunotherapy as first line or second 
line therapy will benefit in term of survival benefit and quality of life in advanced 
stage or unresectable hepatocellular carcinoma
Keywords: hepatocellular carcinoma, immunotherapy, targeted therapy,  
systemic therapy, advanced stage
1. Introduction
During the many years, numerous randomized control clinical studies have been 
performed for testing treatments for advanced hepatocellular carcinoma (HCC) 
[1]. Historical studies performed to prove efficacy of cancer chemotherapy as single 
agent or in combination. However, this class of cancer therapy have had no proven 
benefits on overall survival in advanced stage HCC. Sorafenib a multi-tyrosine 
kinase inhibitor with antiangiogenesic effects showed a survival benefit and it was 
established as first-line systemic therapy for advanced stage HCC patients or pro-
gression form locoregional therapy since 2007. In recent years, there are new agents 
has been approved for advanced stage HCC as first line and second line options. 
Exploratory analyses of these drugs indicate that a cumulative median overall 
survival more than 20 months with good liver function and quality of life.
2. Systemic chemotherapy
Historically, systemic chemotherapy has not shown survival efficacy in treat-
ment of HCC when used in advance stage HCC. This result comes from single-arm, 
open label studies evaluating the use of some traditionally chemotherapeutic, that 
did not lead in the past years and limiting their use in palliative setting or some 
situations. Single agent anthracyclines and fluoropyrimidines have been most 
widely used in clinical practice in the past. Unfortunately, that result reported poor 
response rates and short timing in tumor progression [2]. New chemotherapeutic 
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agents, such as oxaliplatin, have shown clinical benefit in cancers of gastrointestinal 
tract (stomach cancer, colorectal cancer, or pancreatic cancer). These drugs have 
also been evaluated for the treatment of advanced stage setting with some benefit 
findings. As previously said, rational of combination use of chemotherapy might 
be a valuable option for advance stage HCC. FOLFOX4 regimen (Fluorouracil, 
leucovorin, oxaliplatin) was evaluated efficacy in comparison with single agent 
of doxorubicin for advanced stage HCC patients whom ineligible for locoregional 
therapies or surgery in Phase III EACH study [3]. FOLFOX4 had better results in 
term of progression free survival (PFS) (2.93 mons vs. 1.77 mons, P < 0.001) and 
in response rate and disease control rate. Although, these positive results and good 
safety profile in adverse effect but do not necessarily translate to better overall 
survival that is primary endpoint of the study (6.40 mons vs. 4.97 mons, P = 0.07), 
leading to a negatively result of study. Still, an unplanned subsequent analysis 
performed at 7 months after the end of the previous study has shown an improve-
ment of survival outcomes (6.46 mons vs. 4.90 mons, P = 0.04) but progression 
free survival, response rate and disease rate control in the Chinese populations [4], 
leading to FOLFOX4 approval in Chines FDA for advanced HCC. Others, combina-
tion drug, GEMOX regimen (Gemcitabine, oxaliplatin) was evaluated in a large, 
multicenter retrospective study (AGEO) [5]. Results of the study had high response 
rate with 22%, 66% disease control rate and 4.5 months with 11.0 months in term 
of progression free survival and overall survival. This interesting result should be 
considered, response to GEMOX led to better overall survival in comparison with 
lack of response but possible serious side effects of this regimen (Neurotoxicity, 
thrombocytopenia, neutropenia, and diarrhea). Furthermore, studies are therefore 
required in phase III trial to assess the role of this regimen in treatment of advanced 
stage HCC. Some other oxaliplatin-based regimens have been studies in phase II 
studies, showing interesting results, such as XELOX (oxaliplatin plus capecitabine) 
or GP (Gemcitabine plus cisplatin) [6, 7]. Meta-analysis study defined the efficacy 
of oxaliplatin-based regimens but it as an important limitation having evaluated 
only small single arm studies [8].
All this result suggests that better efficacy in some situation could be obtained 
with oxaliplatin-base regimen and GEMOX combination in some setting. But 
current trials are emerging and focusing on targeted therapies and immunotherapy 
that have significantly improve survival outcome.
3. Targeted therapies
The vascular nature of HCC and that vascular endothelial growth factor (VEGF) 
play role of HCC development and metastasis, anti-angiogenesis agents have been 
studies extensively in the setting of advanced HCC. All, this knowledge dramati-
cally leaded changing of systemic therapies form chemotherapy to molecular 
targeted agent. Since sorafenib was established as standard first line therapy in 
advanced HCC.
3.1 Targeted first line therapies
3.1.1 Sorafenib
Sorafenib, a multi-tyrosine kinase inhibitor with antiangiogenic effects is thought 
to be mediated by the blockade of VEGFR 2–3, platelet-derived growth factor 
receptor (PDGFR)-B, and other receptor tyrosine kinases. Sorafenib was approved 
in 2007 by the FDA as first-line therapy for unresectable HCC with BCLC stage C, 
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Child-Pugh class A or BCLC stage B that progressing after locoregional therapy. It 
was recommended in patient with well performance status (Eastern cooperative 
oncology group or ECOG PS 0–2) and preserve liver function test. The efficacy of 
this drug was demonstrated in two phase III, randomized, placebo-controlled clini-
cal trials: the SHARP study [9] and the Asia-Pacific study (ORIENTAL) [10]. The 
patient population was mainly recruited form Europe and North America in SHARP 
study and Asian population in Asia-Pacific study. In the SHARP phase III studies, 
Sorafenib treatment with dose 400 mg twice a day compared to placebo. Among 602 
patients, sorafenib significantly improved overall survival compared with placebo 
(HR 0.69; 10.7 mons vs. 7.9 mons, P < 0.001), DCR (disease control rate) about 
43% in sorafenib arm compared to 32% in placebo arm (P = 0.002). Sorafenib study 
arm had significantly prolong time to radiologic progression in 5.5 mons compared 
with 2.8 mons in placebo arm (P < 0.001), Even though sorafenib prolong time 
to radiologic progression but there is no significant difference in term of time to 
symptomatic progression. Population of this trial was mostly patients with advanced 
stage HCC including 35% with macrovascular invasion and 50% with extrahepatic 
disease. The observed side effects were diarrhea, weight loss, hand-foot syndrome 
and hypophosphatemia. The result of the SHARP trial was subsequently confirmed 
in Asia-Pacific study and in 10 subsequent trials with and median overall survival 
in the range of 10–12 months. Efficacy of sorafenib was conducted in Asia-Pacific 
region population (The ORIENTAL study). The study was performed with the same 
design study to the SHARP trial. The Sorafenib arm group had significantly increase 
overall survival with 6.5 mons compared to 4.2 mons in placebo arm (P = 0.014). The 
overall survival-time and progression free survival time was lower compared to the 
SHARP study. Unfortunately, objective responses rate is poor with 2% by Response 
Evaluation Criteria in Solid Tumors (RECIST) and 10% by modified RECIST 
(mRECIST) [11] and no predictive biomarkers of responsiveness to sorafenib have 
been identified.
From the positively result, Sorafenib was approved with patient who has well 
Child-Pugh score (CTP A only); however, result for the GIDEON (Global inves-
tigation of therapeutic decision in Hepatocellular Carcinoma and its Treatment 
with Sorafenib) study, a large observational study assessing the safety profile and 
efficacy in patients with poor liver dysfunction, the result had a similar safety 
profile irrespective of Child-Pugh scoring [12]. However, Clinical practice guideline 
recommended that sorafenib in patient with underlying liver dysfunction is not 
recommended based on these data alone. The risks and benefits of sorafenib should 
be carefully consideration prior to start.
The recommended dose of sorafenib is 800 mg. Median treatment duration 
is estimated 5–6 months, but early recognition and prevention of toxicities can 
enhance tolerability. Sorafenib toxicities can be manageable. Common toxicities 
are diarrhea, hand-foot skin reaction (HFS), fatigue and hypertension. 35% of the 
patient in the study needed dose reduction and 15% of patients need to withdraw 
from the study due to adverse side effect sorafenib. Liver failure that related to 
sorafenib complications are marginal. Considering the restrictive indication of 
sorafenib in Child-Pugh A class only. However, because of its poor antitumor effect 
and relatively toxicity, developing a new targeted agent with superior efficacy and/or 
lower toxicity has been a critical issue.
3.1.2 Lenvatinib
After sorafenib has been approved for advanced HCC then several studies 
have been conducted to compare sorafenib in front line therapy such as sunitinib 
[13], brivatinib [14], erlotinib [15], linifanib [16] or everolimus [17] without 
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showing superiority (or at least non-inferiority) to sorafenib. Lenvatinib has only 
recently shown non-inferior clinical benefit in REFLECT study [18]. Lenvatinib 
is an oral multi-kinase inhibitor that targets VEGFR 1–3 and fibroblast growth 
factor receptor (FGFR) 1–4, among others. REFLECT study is an open-label, 
Phase III, multicenter, non-inferiority study demonstrated efficacy in Lenvatinib 
compared with sorafenib in patients with advanced HCC (excluding main portal 
vein invasion, clear bile duct invasion and > 50% of tumor to total liver volume 
occupancy). Lenvatinib was adjusted to body weight of patient. The study was 
evaluated in the first line therapy. The study met the primary endpoint of non-
inferiority in overall survival (HR = 0.92, 13.6 mons, Lenvatinib compared 12.3 
mons, sorafenib, 95% CI = 0.79–1.06). Secondary outcomes in PFS and time to 
progression were better for Lenvatinib. Overall response rate (ORR) by mRECIST 
had significant better response (24% versus 9.2% for sorafenib, P < 0.001). This 
drug has shown a higher response rate compared with other tyrosine kinase 
inhibitors (TKIs) and sorafenib. Most common adverse effects compared with 
sorafenib were as follows: hypertension (42% versus 30%), diarrhea (39% versus 
45%) and HFS (27% versus 52%). These results, Lenvatinib was approved as an 
option in first line therapy for advanced HCC.
Arguing for a use of Lenvatinib when rapid tumor shrinkage is warranted. 
Further subgroup analyses showed that Asian populations, patients with hepatitis 
B infection and high serum AFP > 200 ng/mL demonstrated a particular benefit 
form treatment with Lenvatinib. Comparing in term of side effects Lenvatinib was 
associated with more frequent side effects than sorafenib but manageable. More 
important high side effects were hypertension and weight loss for Lenvatinib. 
Based on these documents, current clinical practice guidelines recommended both 
Lenvatinib and sorafenib as frontline therapy for unresectable or advance stage 
HCC that are not amendable to surgery or locoregional therapies [19].
3.2 Targeted second-line therapies
In the SHARP/ASIAN-Pacific and REFLECT studies, it was shown that admin-
istration of TKIs only leads to relatively short periods of tumor control. The recent 
data evaluated the efficacy of targeted therapies in second-line therapy that shown 
clinical benefit in patients with advanced HCC that progressed on prior sorafenib 
therapy in front-line treatment, drugs that considered in this setting was regorafenib, 
carbozantinib and ramucirumab.
3.2.1 Regorafenib
Regorafenib, a multi-kinase inhibitor targeting similar kinases as sorafenib. Phase 
III study (RESOUCE) study [20] was conducted to comparing regorafenib with 
placebo in advanced HCC patients progressing despite sorafenib. The starting dose 
of regorafenib is 160 mg/day (3 weeks on and 1 week off). The primary endpoint 
of this study is overall survival. The study was positive for its primary end points 
(HR = 0.62, P < 0.001, 10.6 months in the regorafenib group vs. 7.8 months in the 
placebo). The secondary endpoints were PFS, ORR and safety profile. Regorafenib 
had significantly prolonged time to disease progression (3.1 versus 1.5 months). The 
efficacy of treatment improved survival in all subgroups of patients. Population 
in this trial, 88% were BCLC stage C and 12% were BCLC stage B, with all of them 
tolerant to sorafenib but progression on treatment. 70% of patients had extrahepatic 
spread and 30% had macrovascular invasion. Around half of patients has high AFP 
more than 400 ng/dL. The response rate was only 10%, based on mRECIST. Median 
time on treatment was 3.5 months. Hypertension was the most common adverse 
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effect, occurring in 15% of patients on regorafenib, followed by HFS. Adverse effects 
led to 51% dose reductions and 10% treatment discontinuation. Sequential adminis-
tration of sorafenib and regorafenib resulted in an OS of 26 months compared with 
19 months in patients receiving only sorafenib as first-line and placebo as second line 
treatment [21].
Regorafenib is the standard of care for patients with advanced HCC who have  
tolerated sorafenib but progressed and recommended in patients with well-preserved 
liver function test (Child-Pugh A class) and good ECOG PS 0–1.
3.2.2 Cabozantinib
Cabozantinib is another TKI targeting VEGFR 1–3, MET, RET and AXL 
[22]. Carbozantinib was approved for thyroid and renal cancer. Phase III study 
(CELESTIAL) [23] compared the efficacy of carbozantinib as second- and third-
line therapy in advanced HCC patients after failure of a sorafenib compared with 
placebo. In contrast to regorafenib, this study allowed the inclusion of patients 
that were intolerant to sorafenib and who had progressive disease on one or two 
systemic therapies. Carbozantinib led to a significant improvement in overall 
survival (HR = 0.76, 95% CI = 0.63–0.92, P = 0.0049, 10.2 mons versus 8.0 mons). 
Other secondary end points such as PFS and ORR were also positive. It is worth 
noting that 27% of the patients had received 2 previous systemic agents. 30% of 
populations in this study presented with macrovascular invasion, 78% with extra-
hepatic spreading and 45% with AFP > 400 ng/dL. Response rate was only 4% with 
carbozantinib based upon RECIST criteria. The most common adverse effects are 
HFS, hypertension, increased level of aspartate aminotransferase (AST), fatigue 
and diarrhea. These adverse effects led to 62% dose reduction and 16% treatment 
discontinuation.
Carbozantinib can be considered for patients who had progressive disease 
on one or two systemic therapies with well-preserve liver function and good 
ECOG PS 0–1.
Because RESORCE and CELESTIAL compared with a placebo arm, it is no data 
shown that which is superior or inferior in term of efficacy to the other. Biomarkers 
have not yet been identified. The RESORCE study recently identified a total of five 
proteins (angiopoietin 1, cystatin B, the latency-associated peptide of TGF-β1, 
oxidized low-density lipoprotein receptor 1 and C-C motif chemokine ligand 3) that 
were associated with prolonged survival with regorafenib [24]. In addition, nine 
plasma miRNAs (MIR30A, MIR122, MIR125B, MIR200A, MIR374B, MIR15B, MIR107, 
MIR320 and MIR645) were correlated with an improved survival. To what extent 
these findings will become clinically relevant remains to be seen.
3.2.3 Ramucirumab
Ramucirumab is a human immunoglobulin G1 (IgG1) monoclonal antibody 
(mAb) that inhibits ligand activation of VEGFR2. Phase III study (REACH) [25] 
conducted for tested efficacy of ramucirumab in term of overall survival in advanced 
HCC after the failure of sorafenib. The primary end point of the study is OS was 
not statistically significant, but a meaningful improvement was observed in sub-
group patients with baseline AFP > 400 ng/mL. Based on these data, the REACH-2 
phase III study [26] analyzed the efficacy of ramucirumab in patients with baseline 
AFP > 400 ng/mL after failure with sorafenib. Result of this study shown ramuci-
rumab significantly improved overall survival from 7.3 mons to 8.5 mons (HR = 0.71, 
95% CI = 0.53–0.95) and median PFS from 1.6 mons to 2.8 mons (HR = 0.45, 95% 
CI = 0.34–0.60) compared with placebo. Overall response rate was 4.6%. The safety 
Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach
6
profile observed in this study was consistent with previously study, only grade III 
adverse effects occurring were hypertension (12.2%) and hyponatremia (5.6%)
Ramucirumab can be considered for patients in second-line therapy with 
baseline AFP > 400 ng/mL with well-preserved liver function and good ECOG PS 
0–1, thus, the AFP may serve as a marker for the benefit of ramucirumab in the 
second line setting for advanced hepatocellular carcinoma. Ramucirumab remains 
the only systemic agent that demonstrated clinical benefit in biomarker selected 
population in HCC.
3.3 Immunotherapy
The most promising immunotherapeutic approach has been the use of immune 
checkpoint inhibitors in vary of cancer type including gastrointestinal malignan-
cies. Immune checkpoint inhibitor can change paradigm of treatment and improve 
survival and quality of life in many type of cancer. Tumor-infiltrating lympho-
cytes (TILs) in the tumor microenvironment was demonstrated in hepatocellular 
carcinoma cell, which shown that HCC is also immunogenic cancer [27]. Some 
studies have also shown the presence of an immunosuppressive intratumoral 
milieu driven by constant exposure of the liver to antigens via the portal system 
and immune dysfunction related to cirrhosis [28]. These results of a phenomenon 
of immune escape might predict that HCC could be response to immunotherapy 
and immune checkpoint inhibitor drugs.
3.4 First-line immunotherapy
Single agent of Immunotherapy has been conducted in two phase III studies 
as first line therapy. The Checkmate 459 trial, Nivolumab compared to standard 
of care as sorafenib, failed to meet the primary endpoint as overall survival [29]. 
Also, with, The KEYNOTE-240 trial of pembrolizumab as second line treatment 
of advance HCC after failure to sorafenib compared with placebo, failed to meet 
endpoints of OS and progression free survival [30]. They are not recommended as 
monotherapy for the treatment of advanced HCC.
To date, new combination immunotherapy with Atezolizumab plus bevacizumab 
were change paradigm of treatment in advanced HCC. This combination therapy is 
the first treatment to demonstrate a significant OS benefit compared with sorafenib 
in Phase III international, open label of patients with locally advanced or metastatic 
and/or unresectable HCC (IMbrave 150 study) [31]. Patients were allocated ran-
domization with 2:1 ratio to compare efficacy of Atezolizumab plus bevacizumab to 
sorafenib. The coprimary endpoints were overall survival and progression free sur-
vival. The combination therapy demonstrated a significant overall survival benefit 
(HR = 0.66, 95% CI = 0.52–0.85). The median overall survival was not reached (Not 
estimate or NE) in the Atezolizumab plus bevacizumab arm, whereas sorafenib arm 
had median overall survival at 13.2 months. The study reported a significantly PFS 
of combination therapy compared to sorafenib (6.8 mons vs. 4.3 mons, HR = 0.59, 
95% CI = 0.47–0.76, P < 0.0001). The difference in overall response rate was sig-
nificant (stratified P < 0.0001): Atezolizumab plus Bevacizumab arm = 27%, and 
sorafenib arm = 12%. Complete response was achieved in 18 patients (6%), which 
is quite promising. The median duration of response of NE and the proportion 
(80%) of responders with a DOR of >6 months by Atezolizumab plus Bevacizumab 
arm therapy indicate a considerable durable response to this treatment. Successful 
benefit both the OS and PFS endpoints at first analysis was surprising and coming to 
a new era of systemic therapy for HCC as standard of care in first-line therapy due to 
meet primary endpoint of overall survival benefit.
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Treatment related adverse effects especially grades III or IV were found more 
in sorafenib arm (46%) compared to Atezolizumab plus Bevacizumab arm (36%). 
Immune-related adverse effects were rarely observed in the Atezolizumab plus 
Bevacizumab arm (expect for infusion reaction in 10.9%, AIHA in 0.3% and adre-
nal insufficiency in 0.3%). Bleeding events form bevacizumab was minimal occur-
ring at 6.4%. The data suggest that the acceptable safety profile in Atezolizumab 
plus Bevacizumab.
However, the median progression free survival is only 6.8 months and only 20% 
of patients do not response to atezolizumab plus bevacizumab, experimental studies 
need to define options for second-line therapy after progression on immunotherapy. 
Most of drugs only been tested after sorafenib intolerance or progression and there 
are currently no phase III study to inform the choice of therapy in this setting. 
However, a clear rationale for offering a targeted therapy given the existing evidence 
for efficacy in first- and second-line therapy.
3.5 Other combination immunotherapies
To current knowledge of combination immune checkpoint blockade plus anti-
angiogenesis translate to new combination therapy that need to find out the clinical 
benefit. Basic research studies show that lenvatinib and anti-PD-1 antibodies have 
synergistic effects [32]. Immunotherapy and Molecular targeting agents as com-
bination therapy might have a role in the treatment of HCC in the future. A phase 
Ib trial of combination use of lenvatinib plus pembrolizumab reported promising 
results [33]. This combination had a median progression free survival and overall 
survival of 9.3 months (95% CI: 5.6–9.7) and 22.0 months (95% CI: 20.4–NE), 
respectively. Overall response rate was higher in 46% (95% CI: 36.0–56.3). A phase 
III trial (LEAP002) of this combination is currently ongoing. On the other hand, 
rationale of dual combination immune checkpoint blockade (PD-L1 plus CTLA-4 
inhibitor) might have a clinical response too. The results of combination therapy 
with the durvalumab (PD-L1 antibody) and the tremelimumab (CTLA-4 antibody). 
The study revealed a median PFS and OS of 2.17 months (95% CI: 1.91–5.42) and 
18.73 months (95% CI: 10.78–27.27), respectively. ORR this combination therapy 
was 24.0% (95% CI, 14.9–35.3). Therefore, this combination therapy is promising, 
and the phase III HIMALAYA trial of this combination is ongoing too.
3.6 Second-line immunotherapy
Second-line therapy after the failure of sorafenib apart from molecular targeting 
agents. Data of immunotherapy both pembrolizumab (an anti-PD-1 monoclonal 
antibody) and nivolumab (a fully humanized monoclonal antibody against PD-1) 
shown efficacy in Phase Ib studies (CheckMate-040 [34] and Keynote-224 [35]). 
Unfortunately, for pembrolizumab, these results were negative in the Phase III 
study, randomized double-blind keynote-240 study, which included a total of 413 
patients with pretreated advanced HCC. The study was comparable with pembroli-
zumab or placebo. The median OS was 13.9 months in the pembrolizumab arm ver-
sus 10.6 months in the control arm (HR: 0.78; P = 0.024), the median PFS was 3.0 
mons versus 2.8 mons (HR: 0.72; P = 0.002). However, since the prespecified alpha 
level was significantly lower, the study must be considered statistically negative. 
CTLA-4 antibodies were also tested in second-line therapy of advance stage HCC; 
The study reported results (response rate was 17.6% and a median time to progres-
sion was 6.48 months) from patients treated with tremelimumab [36]. Nivolumab 
as single agent in advance HCC treated with sorafenib reported an ORR of 14% and 
median OS of 16 months. Due to the promising results the study was conducted 
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the efficacy and safety of the combination of nivolumab and ipilimumab [37]. The 
study was randomized into three different dose and time arms of nivolumab and 
ipilimumab. Of note, the first arm (Nivolumab 1 mg/kg + ipilimumab 3 mg/kg 
every 3 weeks (Q3W) followed by n 240 mg Q2W) demonstrated the most promis-
ing efficacy in term of OS (23 months). ORR and disease control rate were 31% and 
49%, respectively. Interestingly, the different combinations were well tolerated, 
potentially offering a novel treatment option for patients with pretreated HCC.
4. Conclusion
Current data of systemic therapy in advanced stage/unresectable or failure to 
locoregional therapy HCC shown efficacy and safety profile of multiple targeting 
agents such as Lenvatinib, regorafenib, cabozantinib and ramucirumab in addi-
tion to standard treatment with sorafenib. New emerging current standard of 
care in advanced HCC is change to combination therapy with Bevacizumab plus 
atezolizumab as first line therapy due to improvement of progression free survival 
and with overall survival. The increase in available multiple targeting agents and 
immune checkpoint blockade will benefit in many patients. Sequential therapy and 
drug selection will become more challenging as Figure 1. New strategies of systemic 
therapy with new combination therapy are needed to explore.
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